PTHS — Pelthos Therapeutics Share Price
Last trade - 00:00- $10.50m
- $12.87m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | n/a | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 0.2 | n/a | n/a | n/a | n/a | n/a | n/a | -100% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Pelthos Therapeutics Inc., formerly Channel Therapeutics Corporation, is a biopharmaceutical company focused on commercializing therapeutic products for high unmet patient needs. The Company's lead product, ZELSUVMI (berdazimer) topical gel, 10.3%, is used in the treatment of molluscum contagiosum infections (molluscum) in adults and pediatric patients one year of age and older. ZELSUVMI is an FDA-designated novel drug, and a prescription medication approved for the treatment of molluscum that can be administered at home by parents, patients, and caregivers. The Company is also evaluating the path forward for its existing NaV 1.7 development programs for the treatment of various types of chronic pain, acute and chronic eye pain, and post-surgical nerve blocks.
Directors
- Last Annual
- December 31st, 2024
- Last Interim
- March 31st, 2025
- Incorporated
- November 5th, 2024
- Public Since
- February 16th, 2024
- No. of Shareholders
- 16
- No. of Employees
- 4
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NYSE MKT
- Shares in Issue
- 648,501
- Address
- 685 Us Highway One, NORTH BRUNSWICK, 08902
- Web
- https://ir.pelthos.com/
- Phone
- +1 9176446313
- Auditors
- Marcum LLP
Upcoming Events for PTHS
Similar to PTHS
Actinium Pharmaceuticals
NYSE MKT
Aeon Biopharma
NYSE MKT
AIM ImmunoTech
NYSE MKT
Apimeds Pharmaceuticals US
NYSE MKT
Armata Pharmaceuticals
NYSE MKT
FAQ
As of Today at 13:37 UTC, shares in Pelthos Therapeutics are trading at $16.19. This share price information is delayed by 15 minutes.
Shares in Pelthos Therapeutics last closed at $16.19 and the price had moved by +29.48% over the past 365 days. In terms of relative price strength the Pelthos Therapeutics share price has outperformed the S&P500 Index by +15.75% over the past year.
The overall consensus recommendation for Pelthos Therapeutics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out morePelthos Therapeutics does not currently pay a dividend.
Pelthos Therapeutics does not currently pay a dividend.
Pelthos Therapeutics does not currently pay a dividend.
To buy shares in Pelthos Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $16.19, shares in Pelthos Therapeutics had a market capitalisation of $10.50m.
Here are the trading details for Pelthos Therapeutics:
- Country of listing: United States
- Exchange: ASQ
- Ticker Symbol: PTHS
Based on an overall assessment of its quality, value and momentum Pelthos Therapeutics is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Pelthos Therapeutics is $8.50. That is 47.48% below the last closing price of $16.19.
Analysts covering Pelthos Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -$1.10 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Pelthos Therapeutics. Over the past six months, its share price has outperformed the S&P500 Index by +94.12%.
As of the last closing price of $16.19, shares in Pelthos Therapeutics were trading +38.94% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Pelthos Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $16.19.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
We do not have data on Pelthos Therapeutics' directors